Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of BB3 to Improve Renal Function After DCD Kidney Transplantation
2010-019243-19Phase 2Terminated
- Sponsor
- Angion Biomedica Corp.
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in end-stage kidney disease (ESKD) and kidney allograft rejection comparing BB3 with Placebo (2 arms). Primary endpoint: Creatinine clearance over time from donor kidney (Day 0–7). Started Apr 2012; status: terminated.
02
Drugs
terevalefim
03
Conditions
end-stage kidney disease (ESKD)kidney allograft rejection
Beyond the preview
Go deeper on 2010-019243-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019243-19.